# Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

> **NCT06510868** · — · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 45 (estimated)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia

## Interventions

- **RADIATION:** Peptide receptor radionuclide therapy (PRRT)
- **DIAGNOSTIC_TEST:** Blood collection

## Key facts

- **NCT ID:** NCT06510868
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2029-06-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06510868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06510868, "Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06510868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*